Biomarker testing for people with advanced lung cancer in England
File(s)
Author(s)
Type
Journal Article
Abstract
Introduction: Optimal management of people with advanced NSCLC depends on accurate identification of predictive markers. Yet, real-world data in this setting are limited. We describe the impact, timeliness, and outcomes of molecular testing for patients with advanced NSCLC and good performance status in England. Methods: In collaboration with Public Health England, patients with stages IIIB to IV NSCLC, with an Eastern Cooperative Oncology Group performance status of 0 to 2, in England, between June 2017 and December 2017, were identified. All English hospitals were invited to record information. Results: A total of 60 of 142 invited hospitals in England participated in this study and submitted data on 1157 patients. During the study period, 83% of patients with advanced adenocarcinoma underwent molecular testing for three recommended predictive biomarkers (EGFR, ALK, and programmed death-ligand 1). A total of 80% of patients with nonsquamous carcinomas on whom biomarker testing was performed had adequate tissue for analysis on initial sampling. First-line treatment with a tyrosine kinase inhibitor was received by 71% of patients with adenocarcinoma and a sensitizing EGFR mutation and by 59% of those with an ALK translocation. Of patients with no driver mutation and a programmed death-ligand 1 expression of greater than or equal to 50%, 47% received immunotherapy. Conclusions: We present a comprehensive data set for molecular testing in England. Although molecular testing is well established in England, timeliness and uptake of targeted therapies should be improved.
Date Issued
2021-06-01
Date Acceptance
2021-04-06
Citation
JTO Clinical and Research Reports, 2021, 2 (6)
ISSN
2666-3643
Publisher
Elsevier
Journal / Book Title
JTO Clinical and Research Reports
Volume
2
Issue
6
Copyright Statement
© 2021 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/34590024
PII: S2666-3643(21)00035-7
Subjects
Biomarkers
Mutation testing
Non–small cell lung cancer
Personalized medicine
Targeted therapy
Publication Status
Published
Coverage Spatial
United States
Article Number
ARTN 100176
Date Publish Online
2021-04-27